SG11201606427SA - 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis - Google Patents

2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis

Info

Publication number
SG11201606427SA
SG11201606427SA SG11201606427SA SG11201606427SA SG11201606427SA SG 11201606427S A SG11201606427S A SG 11201606427SA SG 11201606427S A SG11201606427S A SG 11201606427SA SG 11201606427S A SG11201606427S A SG 11201606427SA SG 11201606427S A SG11201606427S A SG 11201606427SA
Authority
SG
Singapore
Prior art keywords
cardiomyogenesis
inducers
tri
inhibitors
casein kinase
Prior art date
Application number
SG11201606427SA
Inventor
Filip Laco
Joo Leng Low
Steve Oh
Christina Li Lin Chai
Qixing Zhong
Original Assignee
Agency Science Tech & Res
Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency Science Tech & Res, Univ Singapore filed Critical Agency Science Tech & Res
Priority to SG11201606427SA priority Critical patent/SG11201606427SA/en
Publication of SG11201606427SA publication Critical patent/SG11201606427SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
SG11201606427SA 2014-02-07 2015-02-06 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis SG11201606427SA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201606427SA SG11201606427SA (en) 2014-02-07 2015-02-06 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG2014009815 2014-02-07
SG11201606427SA SG11201606427SA (en) 2014-02-07 2015-02-06 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
PCT/SG2015/050015 WO2015119579A1 (en) 2014-02-07 2015-02-06 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis

Publications (1)

Publication Number Publication Date
SG11201606427SA true SG11201606427SA (en) 2016-09-29

Family

ID=53778275

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201606427SA SG11201606427SA (en) 2014-02-07 2015-02-06 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis

Country Status (5)

Country Link
US (1) US10865384B2 (en)
EP (1) EP3102207B1 (en)
ES (1) ES2926931T3 (en)
SG (1) SG11201606427SA (en)
WO (1) WO2015119579A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202101478YA (en) * 2016-08-18 2021-03-30 Nat Univ Singapore Substituted azole derivatives for generation, proliferation and differentiation of hematopoietic stem and progenitor cells
CN106867961A (en) * 2017-03-27 2017-06-20 广州润虹医药科技有限公司 A kind of induced multi-potent stem cell forms mesoblastemic inducing culture and abductive approach
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
TW202112368A (en) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 Inhibitor combinations for treatment of diseases related to dux4 expression
US20220251092A1 (en) 2019-06-27 2022-08-11 Hangzhou Healzen Therapeutics Co., Ltd. Casein kinase 1epsilon inhibitor, pharmaceutical composition and application thereof
US20230192699A1 (en) * 2020-03-27 2023-06-22 Gritscience Biopharmaceuticals Co., Ltd. Compounds as casein kinase inhibitors
CN113651806A (en) * 2021-06-09 2021-11-16 福建医科大学 Preparation method of 4, 5-diaryl oxazole compound
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions
CN115413669B (en) * 2022-06-14 2024-03-15 湖南大学 Kinase inhibitor and application of composition thereof in improving bacterial wilt resistance of plants

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US208641A (en) * 1878-10-01 Improvement in processes for manufacturing illuminating-gas
NZ274063A (en) 1993-09-17 1997-11-24 Smithkline Beecham Corp Cytokine suppressive anti-inflammatory drug binding protein (csbp) and its use
DE69433501T2 (en) 1993-11-08 2004-11-04 Smithkline Beecham Corp. OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES
AUPM908094A0 (en) 1994-10-27 1994-11-17 Ennio Pty Ltd Improved stitch for elastic netting
EP0797575B1 (en) * 1994-12-13 2003-10-15 F. Hoffmann-La Roche Ag Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase
EP0959885A4 (en) * 1996-11-20 2002-07-17 Merck & Co Inc Triaryl substituted imidazoles and methods of use
WO2003024447A1 (en) 2001-09-20 2003-03-27 Smithkline Beecham Corporation Inhibitors of glycogen synthase kinase-3
EP1532118A2 (en) * 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Imidazole compounds for the treatment of hepatitis c virus infections
WO2007030870A1 (en) 2005-09-12 2007-03-22 Es Cell International Pte Ltd Cardiomyocyte production
US8318489B2 (en) 2005-12-22 2012-11-27 Bruce Paul Davidson Prostacyclin directed differentiation of cardiomyocytes from human embryonic stem cells
PL2493876T3 (en) 2009-10-28 2014-06-30 Pfizer Imidazole derivatives as casein kinase inhibitors
EP2640829A4 (en) * 2010-11-17 2014-06-11 Univ Kyoto Cardiomyocyte- and/or cardiac progenitor cell-proliferating agent and method for proliferating cardiomyocytes and/or cardiac progenitor cells
JP5053433B2 (en) 2010-11-19 2012-10-17 古河電気工業株式会社 Rotating connector device
WO2012084678A1 (en) 2010-12-23 2012-06-28 Syngenta Participations Ag Novel imidazoles useful as plant fungicides
US9598675B2 (en) 2011-10-13 2017-03-21 Singapore Health Services Pte Ltd Method for preparing mesenchymal stem cell-like cells and cardiomyocyte-like cells
WO2013056072A1 (en) 2011-10-13 2013-04-18 Wisconsin Alumni Research Foundation Generation of cardiomyocytes from human pluripotent stem cells

Also Published As

Publication number Publication date
ES2926931T3 (en) 2022-10-31
EP3102207A1 (en) 2016-12-14
EP3102207B1 (en) 2022-05-11
WO2015119579A1 (en) 2015-08-13
EP3102207A4 (en) 2017-09-13
US10865384B2 (en) 2020-12-15
US20170166867A1 (en) 2017-06-15

Similar Documents

Publication Publication Date Title
ZA201700115B (en) Aminopyridazinone compounds as protein kinase inhibitors
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
HK1253372A1 (en) 2-amino-3-fluoro-3-(fluoromethyl)-6-methyl-6-phenyl-3,4,5,6-tetrahydropyridins as bace1 inhibitors
ZA201606844B (en) Method for preparing amg 416
IL257442A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
IL268614A (en) Aminotriazolopyridines as kinase inhibitors
SG11201606427SA (en) 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
AP2016009531A0 (en) Smart thermal patch for adaptive thermotherapy
IL274207A (en) Aminoimidazopyridazines as kinase inhibitors
AU363850S (en) Clip for clothes
ZA201701132B (en) Novel 2,5-substituted pyrimidines as pde inhibitors
PL3145511T3 (en) Composition for treating the eye
IL252986B (en) 3,5-diaminopyrazole kinase inhibitors
HK1257566A1 (en) Bace 1 inhibitors
ZA201606413B (en) 4'-substituted nucleoside-reverse transcriptase inhibitors .
GB201418649D0 (en) 1 for 1 million